BioMarin Pharmaceutical Inc. with ticker code (BMRN) have now 22 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 200 and 69 suggesting an average Analsyt target price of $119.77. Given that the stocks previous close was at $93.93 and the analysts are correct then there would likely be a percentage uptick in value of 27.5%. It’s also worth noting that there is a 50 day moving average of $94.72 while the 200 day moving average is $96.44. The company has a market capitalization of 18.10B. The stock price for the company is currently is currently 95.18 USD
The potential market cap would be $23,073,580,122 based on the market consensus.
USD
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 257.24, revenue per share of 11.69 and a 0.76% return on assets.
